CADRENAL THERAPEUTICS INC
CVKDNASDAQTrading Snapshot
- Day Range
- $1.94 – $1.98
- 52-Week Range
- $1.86 – $14.64
- Volume
- $3.76B
- Avg Volume
- $3.88B
- Shares Outstanding
- 3.1M
- Next Earnings
- Sep 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $503,735
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-5.65
- Dividend Yield
- —
Why Investors Own CVKD
- ✓High-growth profile — revenue up +16.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 70% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About CADRENAL THERAPEUTICS INC
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Cadrenal Therapeutics Consolidates Multi-Indication Strategy For Cardiac Acute Critical Care Franchise, With Focus On CAD-1005 For Both HIT And CSA-AKI
Urgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent need for novel upstream targets, such as 12-LOX, that are being studied to address the root causes of cardio-renal
Cadrenal Therapeutics Unveils Cardiac Critical Care Franchise, Seeks Partners For Late-Stage Cardiovascular Assets
Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditionsCompany is exploring development, licensing, and commercialization
Cadrenal Therapeutics’ Late-Breaking Clinical Data From Phase 2 Study Of 12-LOX Inhibitor CAD-1005 Featured In Oral Presentation At ISTH 2026 Congress
Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in more than a